Skip to main content
. 2015 Jul 17;7:335–345. doi: 10.2147/CLEP.S85496

Figure 3.

Figure 3

Figure 3

Twelve-month persistence with BTA.

Notes: (A) All Medicare patients, (B) all Commercial patients, (C) Medicare patients excluding the patients who died in 2012, and (D) Commercial patients excluding the patients who died in 2012.

Abbreviation: BTA, bone-targeting agent.